Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies for critical care and surgery, announced it has received FDA 510(k) clearance to market a newly designed Arrow® VPS® Stylet. The new design allows Teleflex to provide hospitals with a complete offering of single, double and triple lumen pre-loaded, pressure injectable Arrow® PICC with Chlorag+ard® Technology for use with its current Arrow® VPS® Device platform. Together these technologies provide an easy solution for clinicians who are dedicated to reducing central venous catheter malposition while helping prevent microbial colonization and thrombus accumulation on catheter surfaces.

Eliminating chest X-ray, reducing patient exposure to radiation and providing protection against microbial colonization and thrombus accumulation on catheter surfaces is easier than ever now that the single, double and triple lumen Arrow® PICC with Chlorag+ard® Technology is available pre-loaded with the Arrow® VPS® Stylet.

The Arrow® VPS® Device is designed to replace the need for confirmatory chest X-ray in the presence of a steady Blue Bullseye by using state-of-the-art, real-time intravascular Doppler, ECG and advanced algorithmic logic to notify the clinician that the catheter tip has reached the optimal location.

“Vascular access procedures are one of the most commonly performed in the hospital but are inherently high risk. This has a major impact on hospital reimbursement under the Affordable Healthcare Act," said Jay White, President of the Vascular Division of Teleflex. "We are proud to now provide a full offering of pre-loaded Arrow® PICC with Chlorag+ard® Technology for use with our innovative Arrow® VPS® Devices. The combination of these leading technologies allows us to provide cutting-edge tools to help improve patient outcomes and help solve problems faced by the vascular access clinician every day."

Additional information may be found at www.arrowvascular.com/vps, www.chloragard.com and www.teleflex.com.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rüsch® and Weck® – trusted brands united by a common sense of purpose.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

Teleflex, the Teleflex logo, Arrow, Chlorag+ard, Deknatel, Hudson RCI, LMA, Pilling, Rüsch, VPS, VPS G4 and Weck are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries.© 2016 Teleflex Incorporated. All rights reserved. MC-002067

Teleflex IncorporatedJake ElguiczeTreasurer and Vice President, Investor Relations610-948-2836

Teleflex (NYSE:TFX)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Teleflex Charts.
Teleflex (NYSE:TFX)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Teleflex Charts.